Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag add-on treatment in children with pulmonary arterial hypertension
2022-501012-34-00Phase 3Authorised
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Selexipag plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to disease progression. Planned start Mar 2023; status: authorised.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2022-501012-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501012-34-00.